Boston Scientific Acquires and Launches Fixate (TM) Tissue Band for Spinal Cord Stimulator Leads and Pain Pump Catheters
Innovative Device Quickly Anchors Leads and Catheters

Natick, Mass. (April 15, 2013) – Boston Scientific Corporation (NYSE: BSX) has acquired the fiXate™ Tissue Band and is launching the product in the United States.  The fiXate Tissue Band is a novel suturing device that is designed to enable quick and simple placement of a suture to help secure a spinal cord stimulator (SCS) lead or pain pump catheter.  Boston Scientific introduced the device earlier this month at the annual meeting of the American Academy of Pain Medicine in Fort Lauderdale.  The product was purchased from Anulex Technologies, Inc. 

Designed to manage chronic pain, spinal cord stimulators deliver electrical pulses from an implantable pulse generator to leads with stimulating contacts in order to mask pain signals traveling to the brain. More than 100 million Americans suffer from chronic pain, according to the Institute of Medicine. Living in constant pain for an extended period of time can have a devastating impact on quality of life. 

Anchoring a lead can be a time consuming part of the SCS procedure, and lead migration resulting in the need for revision is a known complication of SCS,” said Richard Bowman, M.D., of the Center of Pain Relief in Charleston, West Virginia. The fiXate device improves the surgical technique by allowing the lead anchor to be secured tightly to tissue in a quick and efficient way with a small anchoring incision.

Bench test data show that, on average, the fiXate Tissue Band can place a suture in under one minute.The semi-automated design provides ease of use for physicians and offers a minimally invasive inline design.

We are pleased to add the fiXate device to our expanding Neuromodulation portfolio,” said Maulik Nanavaty, president, Neuromodulation, Boston Scientific.  “We believe the fiXate device is a significant advance for lead securement, and this acquisition demonstrates our commitment to bringing to the market innovations that are designed to improve patient outcomes.

Indication for Use

The fiXate Tissue Band is intended to be an accessory to the leads/catheter component of Spinal Cord Stimulator/Pain Pump systems functioning to secure the lead to the fascia or inter-spinous/supra-spinous ligament.

About Boston Scientific Neuromodulation

Boston Scientific Neuromodulation is an innovation leader in implantable pain management technology. Through its investments in technology, clinical science, and world-class service, Boston Scientific Neuromodulation is committed to Innovation Focused on Pain Relief™.  For more information on SCS, visit  In 2004, Boston Scientific launched the world’s first rechargeable SCS device, the Precision™ System, which was also the world's first 16-contact implantable SCS device.  Today, more than 60,000 patients worldwide have been treated using Boston Scientific SCS systems.

About Boston Scientific

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend” and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our business plans, new product launches, clinical trials and bench test data, product performance and importance, and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

For further information: Steven Campanini 508-652-5740 (office) Global Media Relations Boston Scientific Corporation Michael Campbell 508-650-8023 (office) Investor Relations Boston Scientific Corporation